Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 4/20 | 0.42 |
| ▸ | PDE9A | O76083 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25000187 | 0.91 | TP53 (0.47) | DRD2TP53LMNAOPRM1HRH3 | |
| SCHEMBL12386859 | 0.84 | DRD2 (0.55) | DRD2DRD3PDE9AOPRM1HRH3 | |
| SCHEMBL12026532 | 0.84 | PDE9A (0.45) | DRD2DRD3TP53PDE9AHRH3 | |
| SCHEMBL25004309 | 0.81 | DRD2 (0.44) | DRD2DRD3HRH3 | |
| SCHEMBL10057674 | 0.77 | HRH3 (0.49) | TP53LMNAHRH3TLR9TLR8 | |
| SCHEMBL12946002 | 0.76 | DRD2 (0.67) | DRD2DRD3LMNAOPRM1 | |
| SCHEMBL19116791 | 0.76 | DRD2 (0.45) | DRD2DRD3HRH3 | |
| SCHEMBL14552934 | 0.75 | DRD2 (0.62) | DRD2DRD3PDE9AOPRM1 | |
| SCHEMBL13558661 | 0.74 | OPRM1 (0.58) | DRD2DRD3OPRM1HRH3 | |
| SCHEMBL25803076 | 0.74 | TP53 (0.46) | TP53PDE9ALMNAHRH3HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | INCYTE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | PIK3R5, PIK3CD, PIK3CA | DRD2 4186/4885DRD3 3934/4885TP53 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.